At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 207 enrolled
Drug / intervention
Nebivolol +1 moredrug
Likely dose
Nebivolol 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blind, Placebo Controlled Study of the Long-Term Efficacy of Nebivolol in Hypertensive Patients After Withdrawal of Therapy
In Brief
A Phase 4 clinical trial evaluating Nebivolol and Placebo for Hypertension. Completed, enrolled 207 participants across 26 sites.
Detailed Summary
This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with stage 1 or stage 2 hypertension after the withdrawal of active medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedNov 5, 2008
Enrollment StartNov 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.7 years ago
Interventions
Nebivololdrug
Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
Placebodrug
Matching placebo tablets, oral administration